Navigation Links
Asterias Biotherapeutics to Participate in Live Google Hangout Discussion of Stem Cell-Based Therapies for Spinal Cord Injury
Date:11/17/2014

MENLO PARK, Calif., Nov. 17, 2014 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today announced that Jane S. Lebkowski, Ph.D., Asterias' President of Research and Development, will participate in a live Google Hangout session presented by the California Institute for Regenerative Medicine (CIRM) discussing the latest progress in stem cell-based therapies for spinal cord injury (SCI).

The CIRM Google Hangout session is scheduled for Tuesday, November 18, 2014, from 12:00 to 1:00pm PT (3:00 to 4:00pm ET). To access the event, please visit http://bit.ly/1sh1Dsm.

The session will include a discussion of Asterias' CIRM-funded Phase 1/2a dose escalation clinical trial for SCI. In addition to Dr. Lebkowski, participants include Roman Reed, a tireless advocate for stem cell research and SCI treatments, and Kevin Whittlesey, Ph.D., a CIRM science officer. Mr. Reed will provide the patient advocate community's perspectives, and Dr. Whittlesey will discuss other CIRM-funded research that aims to better understand SCI and to bring stem cell-based therapies to clinic trials.

About Asterias Biotherapeutics

Asterias Biotherapeutics, Inc. (NYSE MKT: AST) is a leading biotechnology company in the emerging field of regenerative medicine. The Company's core technologies center on pluripotent stem cells, which are characterized by the ability to become all cell types in the human body. Asterias is focused on developing therapies based on pluripotent stem cells to treat diseases or serious injuries in several medical areas where there is high unmet medical need and without adequate available therapies. Asterias' two clinical development programs, AST-OPC1 (oligodendrocyte progenitor cells) for spinal cord injuries and AST-VAC2 (antigen-presenting allogeneic dendritic cells) for lung cancer, are based on the Company's proprietary technology platforms of Pluripotent Stem Cells and Allogeneic Dendritic Cell Immunotherapy, respectively. Additional information about Asterias can be found at www.asteriasbiotherapeutics.com.  

FORWARD-LOOKING STATEMENTS

Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Asterias, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the businesses of Asterias, particularly those mentioned in the cautionary statements found in Asterias' filings with the Securities and Exchange Commission. Asterias disclaims any intent or obligation to update these forward-looking statements.


'/>"/>
SOURCE Asterias Biotherapeutics, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury
2. Asterias Biotherapeutics Announces Investor Briefing Conference Call and Webcast
3. Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution
4. Northwest Biotherapeutics Completes Public Offering Of Common Stock And Warrants; Underwriter Exercises Full Over-Allotment
5. Northwest Biotherapeutics Announces Proposed Public Offering Of Common Stock [and Warrants]
6. Healthpoint Biotherapeutics To Assume Smith & Nephew Name
7. Chrysalis BioTherapeutics, Inc., Receives $1.5m from the National Cancer Institute to Mitigate Radiotherapy-Induced Brain Tissue Damage
8. Northwest Biotherapeutics Announces Registered Direct Offering
9. The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients
10. iBio And Caliber Biotherapeutics Establish License And Collaboration Relationship
11. Northwest Biotherapeutics, Inc. Announces Full Exercise of Over- Allotment Option
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/11/2019)... TORONTO (PRWEB) , ... November ... ... the most rapidly growing drug class and have a major impact in ... patients, important challenges still need to be overcome. Among these, defining valuable ...
(Date:11/11/2019)... ... ... 1st, Dr. Todd M. Britten and the team at Britten Periodontics & Implant Dentistry held ... aware that dental coverage for veterans for major dental surgery can be very hard to ... as many veterans as they could. Dr. Britten says he owes the success of the ...
(Date:11/9/2019)... ... November 08, 2019 , ... ... with extraordinary surgical skills. As a trained sculptor and painter, he combines his ... natural-looking results for each patient. Dr. Sadati has made appearances on TV and ...
Breaking Medicine Technology:
(Date:11/9/2019)... ... ... Mount Sinai Medical-Legal Partnership (MSMLP), an organization formed to address the legal needs ... and advocacy assistance to families and patients in need. The announcement was made at ... of Blaine (“Fin”) Fogg, who was a member of the Boards of Trustees of ...
(Date:11/7/2019)... ... ... ALZYN, LLC today announced that The Silicon Review Magazine has named ALZYN, LLC ... 50 Best Companies to Watch 2019 program identifies companies which are successful in bringing ... on this list indicates the company has distinguished itself from peers by proving itself ...
(Date:11/7/2019)... , ... November 07, 2019 , ... ... co-founder of Ignite and Expand got together on the Shamangelic Healing Podcast ... of downloads skyrocketed. With a trending focus on learning ways to use bio-hacking ...
(Date:11/6/2019)... ... November 06, 2019 , ... ... the participants’ connection to the God of their understanding, as well as, to ... and achieve their life’s purpose, fate, and fortune. , The next Trivedi ...
(Date:11/6/2019)... SOMERSET, N.J. and FRAKFURT, Germany (PRWEB) , ... ... ... Catalent, the leading global provider of advanced delivery technologies, development, and ... announced that its Chair and Chief Executive Officer, John Chiminski, has received ...
Breaking Medicine News(10 mins):